Publications by the researcher in collaboration with Federico Díaz González (33)

2024

  1. Early identification of golimumab-treated patients with higher likelihood of long-term retention

    Frontiers in Immunology, Vol. 15

  2. The complement system is linked to insulin resistance in patients with systemic lupus erythematosus

    Clinical and experimental rheumatology, Vol. 42, Núm. 1, pp. 115-121

2023

  1. Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study

    RMD open, Vol. 9, Núm. 1

  2. Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases

    Advances in Rheumatology, Vol. 63, Núm. 1

  3. Full characterization of the three pathways of the complement system in patients with systemic lupus erythematosus

    Frontiers in Immunology, Vol. 14

  4. HDL Cholesterol Efflux and the Complement System Are Linked in Systemic Lupus Erythematosus

    Journal of Clinical Medicine, Vol. 12, Núm. 16

  5. Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis

    Musculoskeletal Care, Vol. 21, Núm. 1, pp. 189-197

2022

  1. Prevalence of symptomatic axial osteoarthritis phenotypes in Spain and associated socio-demographic, anthropometric, and lifestyle variables

    Rheumatology International, Vol. 42, Núm. 6, pp. 1085-1096

2021

  1. Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years

    Scientific Reports, Vol. 11, Núm. 1

  2. Comment on: Prevalence of systemic lupus erythematosus in Spain: higher than previously reported in other countries? Reply

    Rheumatology (Oxford, England), Vol. 60, Núm. 3, pp. e120-e121

  3. Differences in Capacity of High-Density Lipoprotein Cholesterol Efflux Between Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis

    Arthritis Care and Research, Vol. 73, Núm. 11, pp. 1590-1596

  4. Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry

    Clinical Rheumatology, Vol. 40, Núm. 10, pp. 3979-3988

  5. Prevalence of symptomatic osteoarthritis in Spain: EPISER2016 study

    Reumatologia Clinica, Vol. 17, Núm. 8, pp. 461-470

  6. Role of targeted therapies in rheumatic patients on COVID-19 outcomes: Results from the COVIDSER study

    RMD Open, Vol. 7, Núm. 3

  7. Update of the Position Paper of the Spanish Society of Rheumatology on Biosimilar Drugs

    Reumatologia Clinica, Vol. 17, Núm. 3, pp. 160-169

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

  2. Fracture risk assessment in the general population in Spain by FRAX® algorithm. EPISER2016 study

    Medicina Clinica, Vol. 154, Núm. 5, pp. 163-170

  3. Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: Data from the BIOBADASER III register

    Arthritis Research and Therapy, Vol. 22, Núm. 1

  4. Prevalence of systemic lupus erythematosus in Spain: Higher than previously reported in other countries?

    Rheumatology (United Kingdom), Vol. 59, Núm. 9, pp. 2556-2562

  5. The prevalence of rheumatoid arthritis in Spain

    Scientific Reports, Vol. 10, Núm. 1